| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase POSITIVE ION MODE | ms6647-12 | Grouping:Control | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-17 | Grouping:Control | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-22 | Grouping:Control | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-4 | Grouping:Control | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-5 | Grouping:Control | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-10 | Grouping:Control | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-20 | Grouping:Control | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-25 | Grouping:Control | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-6 | Grouping:Control | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-9 | Grouping:Control | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-15 | Grouping:Weight Losing | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-18 | Grouping:Weight Losing | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-19 | Grouping:Weight Losing | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-2 | Grouping:Weight Losing | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-28 | Grouping:Weight Losing | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-1 | Grouping:Weight Losing | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-14 | Grouping:Weight Losing | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-21 | Grouping:Weight Losing | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-24 | Grouping:Weight Losing | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-27 | Grouping:Weight Losing | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-13 | Grouping:Weight Stable | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-26 | Grouping:Weight Stable | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-29 | Grouping:Weight Stable | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-3 | Grouping:Weight Stable | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-8 | Grouping:Weight Stable | Gender:Female | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-11 | Grouping:Weight Stable | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-16 | Grouping:Weight Stable | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-23 | Grouping:Weight Stable | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-30 | Grouping:Weight Stable | Gender:Male | nmol/vial |
| Reversed phase POSITIVE ION MODE | ms6647-7 | Grouping:Weight Stable | Gender:Male | nmol/vial |
Return to study ST001009 main page
Download data matrix(Acyl Carnitines Concentrations in Muscle Tissue of Muscle Wasting in Cancer Cachexia (part-IV) Reversed phase POSITIVE ION MODE)
- Metabolomics Workbench
|